share_log

B of A Securities Downgrades Beam Therapeutics to Neutral, Announces $35 Price Target

Benzinga ·  Dec 15, 2023 08:37

B of A Securities analyst Greg Harrison downgrades Beam Therapeutics (NASDAQ:BEAM) from Buy to Neutral and announces $35 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment